for EXPOSED SOURCE POPULATION: - Women with a continuous enrolment in the database for ≥ 12 months prior to LMP2 - Women diagnosed with SLE before pregnancy - Women exposed to anifrolumab (polytherapy, added to SLE SOC) during pregnancy and/or 16-week period prior to LMP2

for EXPOSED SOURCE POPULATION: - Pregnancies whose date of conception cannot be established Inclusion criteria for UNEXPOSED SOURCE POPULATION: - Women with a continuous enrolment in the database for ≥ 12 months prior to LMP2 - Women diagnosed with SLE before pregnancy - Women treated with SLE SOC during pregnancy Exclusion criteria for UNEXPOSED SOURCE POPULATION: - Women treated with anifrolumab during pregnancy and/or 16-week period prior to LMP2 - Pregnancies whose date of conception cannot be established Inclusion criteria for EXPOSED and UNEXPOSED STUDY POPULATION: - Women with moderate/severe SLE Exclusion criteria for EXPOSED and UNEXPOSED STUDY POPULATION: - Women with a history of CM or chromosomal abnormalities (according to available records), before delivery - Women prescribed a confirmed teratogenic drug prior to LMP2 with a time period of 5-half-lives of relevant drug or during pregnancy